Tag Archives: QALY

NICE Drugs Policy and the Elderly (NHS Choices)

Summary News of a Department of Health consultation, which involves asking the National Institute for Health and Care Excellence (NICE) to consider “wider societal benefits” (in addition to the burden of illness and the impact a disease has on patients) … Continue reading

Posted in Department of Health, For Carers (mostly), For Doctors (mostly), For Nurses and Therapists (mostly), For Social Workers (mostly), In the News, Management of Condition, National, NHS, NHS Digital (Previously NHS Choices), NICE Guidelines, Non-Pharmacological Treatments, Pharmacological Treatments, Quick Insights, Standards, UK, Universal Interest | Tagged , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , | Leave a comment

Effectiveness and Cost-Effectiveness of Donepezil, Galantamine, Rivastigmine and Memantine for the Treatment of Alzheimer’s Disease (Health Technology Assessment)

[A version of this item appears in: Dementia: the Latest Evidence Newsletter (RWHT), Volume 2 Issue 11, June 2012]. Summary The purpose of this Health Technology Assessment was to review and update guidance to the NHS in England and Wales … Continue reading

Posted in Acute Hospitals, Community Care, For Doctors (mostly), For Researchers (mostly), Management of Condition, National, NHS, NIHR, Pharmacological Treatments, Proposed for Next Newsletter, Systematic Reviews, UK | Tagged , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , | Leave a comment